Search

Your search keyword '"Griffiths, Christopher A."' showing total 220 results

Search Constraints

Start Over You searched for: Author "Griffiths, Christopher A." Remove constraint Author: "Griffiths, Christopher A." Publisher elsevier bv Remove constraint Publisher: elsevier bv
220 results on '"Griffiths, Christopher A."'

Search Results

1. A genome-wide meta-analysis of palmoplantar pustulosis implicates Th2 responses and cigarette smoking in disease pathogenesis.

2. Estimating the burden of vitiligo: a systematic review and modelling study

3. Cross-Comparison of Inflammatory Skin Disease Transcriptomics Identifies PTEN as a Pathogenic Disease Classifier in Cutaneous Lupus Erythematosus

4. Influence of autozygosity on common disease risk across the phenotypic spectrum

5. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics

6. Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicentre phase 3 double-blind randomised placebo-controlled trial (ViDiKids)

7. Damaging Alleles Affecting Multiple CARD14 Domains Are Associated with Palmoplantar Pustulosis

8. Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics

9. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease

10. Characterising Sources of PM 2.5 Exposure for School Children with Asthma in Six Sub-Saharan African Cities

11. Long-Term Air Pollution Exposure and Risk of SARS-CoV-2 Infection and CPVOD-19 Severity: A UK-Wide Cohort Study (COVIDENCE UK)

12. Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial

13. Global Biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts

15. Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)

16. Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis

17. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease

21. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis

23. Determinants of Antibody Responses to Two Doses of ChAdOx1 nCoV-19 or Bnt162b2 and a Subsequent Booster Dose of BNT162b2 or mRNA-1273: Population-Based Cohort Study (COVIDENCE UK)

25. Dermatology COVID-19 Registries

27. 28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

28. 26874 Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial

29. 27043 Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

31. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study

33. Fidelity of yellowfin tuna to seamount and island foraging grounds in the central South Atlantic Ocean

34. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials

35. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries

36. Psoriasis

37. Inflammaging and the Skin

38. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease

39. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

40. Risk Factors for Developing COVID-19: A Population-Based Longitudinal Study (COVIDENCE UK)

41. Determinants of Pre-Vaccination Antibody Responses to SARS-CoV-2: A Population-Based Longitudinal Study (COVIDENCE UK)

42. 14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)

43. 13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis

45. 15308 Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years

46. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

48. Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease

49. International collaboration and rapid harmonization across dermatologic COVID-19 registries

Catalog

Books, media, physical & digital resources